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Abstract
Background: To reduce the coronavirus disease burden in England, along with many other countries, the
government implemented a package of non-pharmaceutical interventions (NPIs) that have also impacted other
transmissible infectious diseases such as norovirus. It is unclear what future norovirus disease incidence is likely to
look like upon lifting these restrictions.
Methods: Here we use a mathematical model of norovirus fitted to community incidence data in England to
project forward expected incidence based on contact surveys that have been collected throughout 2020–2021.
Results: We report that susceptibility to norovirus infection has likely increased between March 2020 and mid-2021.
Depending upon assumptions of future contact patterns incidence of norovirus that is similar to pre-pandemic
levels or an increase beyond what has been previously reported is likely to occur once restrictions are lifted. Should
adult contact patterns return to 80% of pre-pandemic levels, the incidence of norovirus will be similar to previous
years. If contact patterns return to pre-pandemic levels, there is a potential for the expected annual incidence to be
up to 2-fold larger than in a typical year. The age-specific incidence is similar across all ages.
Conclusions: Continued national surveillance for endemic diseases such as norovirus will be essential after NPIs are
lifted to allow healthcare services to adequately prepare for a potential increase in cases and hospital pressures
beyond what is typically experienced.
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Background
In late January 2020, COVID-19 was first detected in the
United Kingdom (UK) [1], and in response to increasing
incidence and hospitalisations, the UK entered the first
of three national lockdowns on the 23rd of March 2020.
The lockdowns and other social restrictions resulted in a
reduction in contact patterns in the community, as
shown through self-reported contact rates collected
using online surveys [2] and other metrics [3]. Subse-
quently, reports to national surveillance for many en-
demic diseases, including norovirus, declined across
England throughout the rest of 2020 [4]. This reduction
in reports of infectious disease has been consistent
across many pathogens and observed in other countries
where non-pharmaceutical interventions (NPIs) for the
control of COVID-19 have been implemented (e.g.
Australia [5, 6] and the USA [7, 8]). With the introduc-
tion of vaccination against COVID-19 in England, a con-
siderable reduction in COVID-19 hospitalisations and
deaths has been observed and this intervention has su-
perseded the blunt tool of NPIs. The UK roadmap out
of lockdown details the gradual relaxation of NPIs in
2021 [9], which will likely result in contact patterns
more consistent with those seen prior to 2020.
Norovirus is an endemic viral infection present glo-
bally across high- and low-income countries with—as
yet—no commercially available vaccine [10]. Norovirus
infection can be asymptomatic or can result in gastro-
intestinal disease symptoms such as stomach cramps,
diarrhoea and vomiting. In more vulnerable groups, such
as the elderly or immunocompromised, norovirus can
result in more severe and/or prolonged disease, and af-
fected individuals may require hospitalisation for treat-
ment. A recent analysis of hospital data in England
ascribes an average of 40,800 (with an interquartile range
(IQR) of 40,500–41,400) hospital episodes where noro-
virus was the primary diagnosis and a further 61,500
(IQR 58,700–62,500) with norovirus as a secondary diag-
nosis, meaning that norovirus is a significant public
health and economic burden in England [11] and during
hospital outbreaks can result in ward closures.
Norovirus-associated mortality within Europe has been
estimated as 0.2 (95% uncertainty interval 0.1–0.2)
deaths per 100,000 persons [12], which is at least 100-
fold less than equivalent estimates for all-cause influenza
illness [13]. Norovirus is the most common cause of
gastrointestinal infections globally and has the highest
burden of disease for intestinal infections in the UK [14].
Infections and outbreaks occur more frequently in the
winter months, and in England are monitored through
multiple national surveillance systems (e.g. [15]) to en-
sure that unusual activity is detected and that alerts to
local health authorities are made for preventive actions.
The probability of symptomatic disease is also influenced
by host genetic factors [16], the infectious dose of noro-
virus [17] and previous exposure to infection. Norovirus
genetic diversity is characterised by classifying isolates
into genogroups, genotypes and strains (also termed var-
iants) [18]; since 2012, the GII.4 genotype 2012 strain
(shortened to ‘GII.4/2012’) has dominated in reports of
symptomatic disease in England and globally. Prior to
the GII.4/2012 strain, population strain replacement oc-
curred every few years and was consistent across wide
geographies. During these strain replacement events, in-
creased norovirus activity in the first year is typically ob-
served, resulting in increased strain on health services
[19]. While each dominant strain is termed dominant
because it is isolated from a majority of cases in most
settings, there is a considerable genetic diversity of the
remaining isolates, and the evolutional impact of this re-
mains unclear. The majority of norovirus infection is
considered to occur via community transmission, and
consequent changes in community contact patterns will
likely influence norovirus transmission. However, noro-
virus has multiple routes of transmission; for example
foodborne transmission is thought to contribute to ap-
proximately 16–35% in the UK, based on microbial risk
assessments and detailed case investigations [20].
Here we illustrate through modelling the impact of
COVID-19 NPIs used throughout 2020–2021 on the dy-
namics and incidence of norovirus disease in the com-
munity, leading on from a recent report of a reduction
in norovirus activity [4]. We provide indicators of sur-
veillance to inform what early warning of a norovirus re-
surgence may look like.
Methods
Modelling norovirus infection prior to the COVID-19
pandemic (up until March 2020)
We built an age-structured susceptible-exposed-
infectious-recovered (SEIR)-like model that follows a
previously developed model for norovirus, focussing on
infections with the GII.4/2012 strain [21] (Fig. 1). We as-
sume a population of 100,000 individuals with an age
structure similar to that reported in England, and that
20% of the population remain resistant to norovirus in-
fection due to the nonsecretor status of human histo-
blood group antigen carbohydrates [22]. Upon infection,
individuals are assumed to enter a short stage of expos-
ure (or pro-dromal infection) and then become fully in-
fectious and symptomatic for on average of 2 days [23,
24] (full details of the model, including differential equa-
tions and parameters, are given in ‘Additional file 1’). In-
dividuals then enter the asymptomatic stage, where they
remain moderately infectious [25] for on average 15 days
when compared to the symptomatic stage but have no
symptoms of disease [26]. Asymptomatic infection is as-
sumed to correspond with norovirus shedding in stool
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that can be detected using RT-PCR. Upon recovery, in-
dividuals are immune to further symptomatic infection,
but can develop an asymptomatic infection. After an
average of 5.1 years, individuals are assumed to return to
the susceptible class where the infection will be symp-
tomatic again [21]. To capture heterogeneity in trans-
mission between ages, the transmission model is age-
structured using eight age groups (0–4, 5–14, 15–24,
25–34, 35–44, 45–54, 55–64, 65+). Symmetric contact
rates between and within age groups prior to March
2020 were obtained for England from the European
Polymod Study [27] and adapted for the age ranges used
in here (using the R package socialmixr). All modelling
and analyses were done in the software R (v 4.0.4).
A challenge of norovirus modelling is that there are
broad observations in the epidemiology of norovirus
which a model should ideally replicate, but these obser-
vations are from a wide spectrum of sources, with limi-
tations and biases within each dataset. In the UK, there
have been two major studies in recent decades into in-
fectious intestinal diseases (IID), which provide valuable
information on community incidence. The first Study of
Infectious Intestinal Disease (IID1) in England illustrated
that norovirus is a common cause of IID in the commu-
nity with considerable under-reporting to primary care
[23]. A follow-on study (IID2) explored community inci-
dence of gastrointestinal diseases (including norovirus),
where incidence was highest in children and declined
with age [28], and there was substantial under-reporting
within the passive surveillance at the time. Serological
data for norovirus is limited (due to challenges in estab-
lishing reliable correlates of protection [29] and enzyme
immunoassays often being insensitive to strain-specific
immunity), but where available, serological responses
indicate seroconversion after acute illness [30] and sug-
gest an increasing titre with exposure. In order to cap-
ture these general observations while needing to obtain
reliable transmission rates within the community, we fit
the probability of transmission given a contact to com-
munity age-stratified incidence data from IID2 [31]
under different assumptions stated above and also in-
clude a 20% under-reporting of symptomatic cases to ac-
count for a possible increase in incidence from the
GII.4/2012 strain which has dominated symptomatic ill-
ness since this time. This one parameter is fitted using a
Metropolis-Hastings algorithm, full details of the fitting
procedure are provided in ‘Additional file 2’. For each
scenario, we provide estimates of incidence (i.e. new
cases of symptomatic infection) which were compared
directly to incidence data. Additional model outputs
were provided as a form of validation against what we
would expect a realistic model of norovirus to output;
estimates asymptomatic prevalence, a proxy for sero-
prevalence (assumed here to be the proportion of indi-
viduals that have recently recovered from symptomatic
infection) and estimates of R0. Estimates of R0 were ob-
tained for the pre-COVID-19 scenarios by running the
model to endemic equilibrium and estimating R0 assum-
ing R0 = 1/Pr(S). While the fit of the model to the data
is the main criteria for model selection, we consider
these additional metrics when making decisions on the
appropriateness of each set of model assumptions.
While the above model assumptions align well with
much of the evidence, there are uncertainties with some
assumptions, and alternative assumptions may affect dis-
ease dynamics. As part of sensitivity analysis, we add-
itionally include other models which capture the main
uncertainties and compare the fit of these models to the
Fig. 1 Schematic of the model for norovirus transmission. Each box represents a compartment of the system of equations; S susceptible, E pre-
infectious, I infectious and symptomatic, A infectious and asymptomatic, R recovered and G genetically resistant to infection. Dashed boxes
illustrate the assumed relationships between the model outputs and available data. The parameters specified in the figure are those used in the
main model, see the supplementary information for additional assumptions tested as part of the sensitivity analysis
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data and other summary metrics (see ‘Additional file 3’
for full details).
Modelling norovirus infection during 2020–2021
From March 23, 2020, onwards, we assume that the age-
specific contact rates change as reported in a longitu-
dinal cross-sectional study (‘Comix’) of in-person con-
tacts in England [32]. Weekly measures of age-specific
contact rates were collected from March 24, 2020, and
the study will continue to collect additional surveys until
September 2021. The weekly contact rates are grouped
into nine distinct periods of time including 3 different
lockdowns that saw different degrees of NPIs being in-
troduced and restrictions easing again with varying con-
tact rates [33]. The model is first run to endemic
equilibrium using pre-pandemic values of age-specific
contact rates. Between March 23, 2020, until July 19,
2021, a contact matrix from Comix is used for each
period of time (specified in ‘Additional file 4’). For later
projections, we assume that contact rates return to pre-
2020 values, an additional scenario that assumes adults
only return to 80% of their pre-pandemic contact rates.
We report the expected incidence of symptomatic noro-
virus infections in time, the proportion of the population
susceptible to symptomatic infection. R0 was also esti-
mated for each time-period; to do this, we assume that
only the contact rates have varied and so use the propor-
tional change in the dominant eigenvalue of contact
matrices (ϑ) to estimate R0(t), where R0(t) = Ro/ϑ.
To support planning and national surveillance, we
translate the incidence reported within the model to
expected norovirus cases reported to the national Sec-
ond Generation Surveillance System (SGSS). The SGSS
is the national laboratory reporting system which re-
cords positive records of causative agents such as noro-
virus in England from frontline diagnostic laboratories
[15]. As norovirus is not a notifiable causative agent in
England under the Health Protection (Notification) reg-
ulations 2010 [34]. Data were extracted on June 28,
2021, for all specimen types from January 1, 2014, on-
wards and were deduplicated, providing an estimate of
the weekly number of norovirus cases reported to SGSS.
From the model, the weekly incidence of symptomatic
norovirus per 100,000 was scaled up to national inci-
dence (using Office for National Statistics data on popu-
lation size for England in 2019 of 56,290,000
individuals). Using the estimates within Tam et al. [14],
we assume that for 287.6 (95% CI 239.1 to 346) symp-
tomatic cases estimated nationally one case is reported
within the SGSS. The data were compared to the model
and the percentage difference reported, noting that the
under-ascertainment reported in Tam et al. is from a la-
boratory reporting surveillance system in place prior to
SGSS meaning that some changes in under-
ascertainment are expected.
Results
The age-specific incidence of norovirus observed in Eng-
land is best replicated assuming that primary infection is
symptomatic, the duration of asymptomatic infectious-
ness is 15 to 20 days, and that asymptomatic infection is
considerably less infectious than symptomatic infection
Fig. 2 Comparison of the norovirus model to A data from Harris et al. of age-specific incidence of symptomatic norovirus infection where this fit
was used to estimate the probability of transmission given a contact, B weekly reported cases of norovirus reported to the SGSS system (thick
brown line—5 year average, thin brown lines—minimum and maximum). The model incidence (per 100,000 person-years) was extrapolated to a
national level, accounting for known under-reporting and under-ascertainment inherent in the surveillance data (287.6 (95%CI 239.1–346.0)) and a
further 27% reduction in incidence in the model for alignment with the reported data. Dashed lines indicate the first day of each calendar
month. SGSS Second Generation Surveillance System
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(Fig. 2A and Table 1). Simulations that correspond to
these observations resulted in a shedding prevalence of
less than 1%, the proportion of the population recently
recovered from an infection ranging from 24.54 to
30.55% and an R0 between 1.81 and 2.01. The age-
specific incidence of symptomatic infection is highest in
children aged <5 years, and incidence declines with age.
When we compare this modelled incidence to the
weekly SGSS 5-year average (from norovirus year 2014/
15 to 2018/19), a further 27% reduction in reporting is
needed for cases to be equivalent (Fig. 2B). Other
models with different assumptions had a poorer fit to
the data and were not taken further in the analysis.
From March 23, 2020, (‘lockdown 1’) until September
4, 2020, (the ‘School reopening’ stage), the rate of infec-
tion for norovirus is sufficiently low that new infections
are rare (Fig. 3A), and an increase in population suscep-
tibility is observed (Fig. 3B). This period corresponds
Table 1 Summary of model assumptions trialled for norovirus, where each model was fitted to age-specific incidence data in
England. Models A0–B20 were taken forward to estimate incidence of norovirus between 2020 and 2022
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with minimal cases reported to the laboratory surveil-
lance SGSS system (Figure S1). This period corre-
sponded with an R0 for norovirus ranging from 0.43 to
0.77, meaning that transmission could not be sustained.
The period between September 4, 2020, to January 5,
2021, corresponds to a higher average number of con-
tacts within the population (up to 7.79 in the average
number of (unweighted) contacts), an increase of inci-
dence in the model, and outside of the second lockdown
and the Christmas period, R0 was above 1.00 (see ‘Add-
itional file 4’). This increase in incidence was not ob-
served in the SGSS system. The subsequent ‘lockdown 3’
period corresponds to a reduction in contacts (from 6.61
to 3.47), and the rate of infection falls to low levels
again, until schools are re-opened on March 9, 2021
(Fig. 3A). By this time point, the model estimates that
the proportion of the population susceptible to
symptomatic infection has risen from 54 to 59% (a 9%
increase) as a result of waning immunity (Fig. 3B, age-
specific values given in Additional file 1: Table S1). Sub-
sequently, model scenarios predict a rise in the rate of
infection and a resurgence of norovirus in the commu-
nity resulting in an annual incidence of cases up to 2-
fold higher than simulations prior to 2020 (Fig. 4A, full
details in Additional file 1: Table S1). This time period
also corresponds with an R0 above 1.00, where the con-
tact data collected while schools correspond to an esti-
mated R0 of 1.28. However, this prediction is dependent
upon assumptions on mixing patterns in the general
population; if adult mixing is assumed to be 80% of pre-
COVID levels, an increase in incidence is not predicted.
Instead, the rate of infection increases but at a lower
level, resulting in a gradual increase in susceptibility in
the population.
Fig. 3 Estimates of the impact of changing contact patterns due to COVID-19 restrictions on norovirus A incidence and B susceptibility to
symptomatic infection from January 2019 to June 2023. In each panel, each colour represents simulations that assumptions contact patterns after
July 2021 are the same as pre-COVID-19 (light red) or adults have 80% fewer contacts (red), and allowing for different assumptions about under-
reporting of norovirus incidence within Harris et al. [31]; solid lines assume no under-reporting and dashed lines assume 20% underreporting. UP
under-reporting, sim simulated duration of asymptomatic infectiousness in days
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We also tested the impact of model assumptions re-
garding under-reporting and the duration of shedding
(Figure S2). Assumptions about under-reporting affect
the rate of infection; if incidence was under-reported in
Harris [31], this will result in a higher rate of infection
in the community and the potential for a more rapid
change in incidence. Assumptions on the duration of
shedding have a lesser impact; simulation assuming a
shorter duration of shedding suggests a higher incidence
in the 2021/22 norovirus year (Additional file 1: Table
S1).
Discussion
The reduced reporting of norovirus cases and outbreaks
that were observed in 2020 as a consequence of COVID-
19-associated NPIs has been described within a number
of countries, including England [4], Australia [5] and the
USA [7, 8]. Our modelling study quantifies the potential
unintended consequences of the build-up of individuals
susceptible to norovirus infection in England, with epi-
demic potential for the autumn/winter of 2021 and
2022. Norovirus is an example of an endemic infectious
disease where changes in contact rates can affect both
the short and long-term incidence of symptomatic dis-
ease. This resurgence is likely to further increase ‘winter
pressures’ within the NHS that may lead to more hos-
pital admissions due to norovirus, hospital outbreaks of
norovirus with bed-days lost as beds are kept empty for
infection prevention and control, and treatment delays
for non-norovirus patients [11, 35]; therefore, prepara-
tions for mitigating the effect of an increase in incidence
are essential. This is especially true at the current time
where there has been considerable disruption to health-
care services due to the COVID-19 pandemic and there
are a record number of 5 million people on waiting lists
to receive hospital care following the impact of COVID-
19 in England [36]. While there are several caveats of
the modelling to consider in the interpretation of this
analysis, this is the first analysis of disease dynamics for
norovirus affected by changes in NPIs.
More broadly, the unintended consequences of NPIs
are likely to be widespread across other endemic diseases
(e.g. respiratory syncytial virus and influenza 37) where
incidence pre-COVID-19 was limited by populations be-
ing largely immune to infection [38, 39]. A challenge in
the interpretation of the likely future trajectory of inci-
dence is the quantification of how NPIs impact physical
contacts in the community and how this impacts the
transmission of infectious disease. Here we make use of
the longitudinal cross-sectional study of contacts, which
has been instrumental in predicting the incidence of
COVID-19 [40], and show that these data can be very
useful for quantifying dynamics of endemic diseases in
addition to COVID-19. Continued collection of these
data and incorporation into models of infectious disease
will be essential in informing our understanding of dis-
ease transmission as the pandemic continues to unfold.
It is likely that the impact of NPIs on norovirus, respira-
tory syncytial virus and influenza was more pronounced
than for SARS-CoV-2 because the effective reproduction
number (Re, equivalent to R0 multiplied by the propor-
tion susceptible) for these endemic pathogens is close to
1.00. Theoretically, the NPIs are designed to limit con-
tact rates, which will reduce R0 and in turn Re. At least
Fig. 4 Model estimates of A incidence of symptomatic norovirus infections by age and norovirus year, B predictions of cases reported within
SGSS for the 2021/2022 year, compared with a typical norovirus year. Simulations assuming a duration of shedding of 15 days and no under-
reporting (outcomes from other simulations are shown in ‘Additional file 5’). Dashed lines indicate the first day of each calendar month. SGSS
Second Generation Surveillance System
O’Reilly et al. BMC Medicine          (2021) 19:299 Page 7 of 10
in the period of time that has been experienced, this will
limit transmission and disease incidence, as we have ob-
served. The impact of further restrictions should still be
effective, but with increases in susceptibility, the indirect
effect of NPIs on endemic diseases could become less ef-
fective with time. Our analyses make the implicit as-
sumption that contacts described within surveys
correlate with contacts relevant for infectious disease
transmission where the primary mode is direct contact,
while this is apparent for infections such as influenza
and SARS-CoV-2, there is less evidence for norovirus.
These assumptions explain why the rate of infection is
predicted to increase when contacts correspond to an R0
above 1.00. The reported incidence of norovirus in the
coming months, the changing behaviours of the commu-
nity in contacts and infection prevention, and the actions
public health officials will take to prevent a large epi-
demic, will be the test of this hypothesis. As the
COVID-19 pandemic evolves, potentially including more
transmissible and vaccine-evading variants, NPIs that in-
clude the ongoing working-from-home recommendation
through to school closures and lockdowns, remain pos-
sible. A major assumption of our model, which reflects
the current understanding of norovirus epidemiology, is
that contacts with and between children under 5 years
are the main driver of norovirus transmission. Conse-
quently, any changes in contact with this age group will
have a large effect on norovirus dynamics.
In the analysis, the incidence of norovirus reported
was replicated well in the simulations, with the excep-
tion of the expected increase in cases at the end of 2020.
This potentially suggests that the rate of infection as-
sumed in the model is higher than is experienced in the
community, despite the fact that the rate of infection
was fitted to community data. Alternatively, the effect of
reduced to the SGSS due to changes in healthcare-
seeking behaviours and reduced laboratory testing of
samples obtained may have impacted on the comparator
data. This observation means that some caution should
be applied to the findings presented here as the model
predictions are sensitive to assumptions about contact
rates and the probability of transmission, which remain
uncertain. Further work will explore this in more detail
through the use of additional contact surveys and ex-
ploration of other datasets that can improve our under-
standing of norovirus transmission in the community.
The majority of norovirus disease occurs within the
community; there is a significant disease burden result-
ing in school closures and days of work lost (especially
as infection can be experienced relatively frequently)
[41]. Hygiene measures, such as handwashing with soap,
enhanced environmental cleaning and staying at home
when ill, have been part of the usual recommended
practice to reduce norovirus transmission, but the
COVID-19 pandemic has indirectly enforced the adher-
ence to these measures. It is possible that beyond 2021,
these measures may remain as usual practice in the
short to medium term, which may well mean that the
incidence of infectious diseases such as norovirus is low-
ered compared with historical norms. An additional
challenge of norovirus largely being a community illness
is that norovirus surveillance is affected by both under-
ascertainment and under-reporting, resulting in consid-
erable uncertainty in true estimates of burden. With an
increase in community transmission of norovirus, we
would expect an increase in incidence, including severe
disease in institutional settings (such as care homes for
the elderly). However, much of the COVID-19 interven-
tions targeted at institutional settings may also limit the
incidence of norovirus; the impact of these interventions
on norovirus warrants investigation. While we compared
the model output to cases reported into the SGSS, sur-
veillance is biased towards cases within hospitals, which
will be a combination of community and hospital-
acquired infections. For this reason, we have fitted to
data from a community cohort study and used the SGSS
data as a validation of the model estimates. The data
from IID2 is over 10 years old, and may not fully repre-
sent incidence experienced in recent years, due to strain
replacement in 2012 and hypothesised higher incidence
of infection. Indeed, a recent community cohort study in
the Netherlands report an incidence of symptomatic
norovirus of 339.4 cases per 1000 person-years [42],
which is higher than that reported in the IID2. We
aimed to overcome the weaknesses in data by having
multiple models with varying assumptions to cover a
wide range of plausible present-day scenarios of noro-
virus dynamics. We identified a difference between
model predictions and SGSS of 73%, which is well within
a plausible range.
A further complexity in norovirus epidemiology is the
possibility of strain replacement in the coming months
or years; the GII.4/2012 strain has been in circulation in
England since 2013 and could continue to dominate, but
the emergence of other variants also has the potential
[43]. The likelihood and how a new variant may impact
norovirus dynamics are currently uncertain and are
likely to depend on the relative virulence of a new strain
and the heterotypic immunity from infection with the
GII.4/2012 strain. Further work will include consider-
ation of strain-specific immunity profiles within the
community to understand the impact of multi-strain dy-
namics and the potential impact of vaccination.
Conclusions
This modelling study suggests that norovirus incidence
in the community is likely to remain approximately simi-
lar to or substantially increase beyond what has been
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experienced in years prior to 2020. The results are sensi-
tive to future contact patterns in the community, and
the adherence to preventive actions, which will affect the
probability of transmission. The lower incidence of nor-
ovirus reported in surveillance aligns with model as-
sumptions on reduced contact rates from March 2020 to
June 2021 and is consistent with an increase in popula-
tion susceptibility. The short- to long-term impact of
this increased susceptibility places populations at risk of
norovirus disease, but the scale of the impact remains to
be seen. Continued investment to maintain robust na-
tional surveillance systems will remain critical to enable
measures to limit the impact of these resurgences and
provide essential information to public health bodies to
support the implementation of preventive actions.
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